Raman-triggered ablation/resection systems and methods

Patent metadata

Field	Value
Publication number	US-10888227-B2
Application number	US-201414464642-A
Country	US
Kind code	B2
Filing date	Aug 20, 2014
Priority date	Feb 20, 2013
Publication date	Jan 12, 2021
Grant date	Jan 12, 2021

Abstract

Apparatus and methods are presented herein that permit real-time, accurate detection of residual tumor in the operating room. The Raman-based wide-field imaging apparatus and methods described herein permit real-time imaging of tumor-targeted R-MR nanoparticles over a wide field. Apparatus and methods are presented herein for operating a Raman-based resection system.

First claim

We claim:

1. A system comprising:
a Raman particle to be administered to a subject, wherein the Raman particle is a Surface Enhanced Resonance Raman Scattering (SERRS) nanoparticle comprising a nanoscale substrate, a capping agent associated with the substrate, and a Raman active agent, wherein the capping agent is a member selected from the group consisting of a citrate, a citric acid, an ascorbic acid, an ascorbate, a palmitoylascorbate, a tetrakis(hydroxymethyl)phosphonium chloride, and an amino acid, and the Raman active agent is characterized by sufficient affinity for the nanoscale substrate to permit displacement of the capping agent, thereby providing a high density and localized loading of the Raman active agent onto the Raman particle, such that the Raman active agent is in direct contact with the nanoscale substrate and positioned a distance between 1 nm and 10 nm from the nanoscale substrate;
an ablation laser for directing electromagnetic radiation onto or into a scanning point of a target tissue of the subject containing the administered Raman particle;
an instrument operably linked to the ablation laser, the instrument comprising optics for directing the electromagnetic radiation onto or into the scanning point of the target tissue of the subject containing the administered Raman particle;
a detector for detecting scattered photons emanating from the scanning point of the target tissue of the subject containing the administered Raman particle, said scattered photons resulting from illumination with the electromagnetic radiation; and
a processor configured to regulate output power levels of the ablation laser and to process data corresponding to the scattered photons detected from the scanning point of the target tissue of the subject containing the administered Raman particle,
the processor being configured to trigger a switch from an interrogation power level of the ablation laser to an ablation power level of the ablation laser upon a determination of a presence of the administered Raman particle in the target tissue of the subject in and/or upon the scanning point, the ablation power level being sufficient to ablate tissue at the scanning point.

2. The system of claim 1 , wherein the electromagnetic radiation has a wavelength of about 500 nm to about 11 μm.

3. The system of claim 1 , wherein the instrument is an endoscopic instrument.

4. The system of claim 1 , wherein the ablation laser is selected from the group consisting of a CO 2 laser, an Er:YAG laser, and a Nd:YAG laser.

5. The system of claim 1 , wherein the instrument comprises optics for imaging.

6. The system of claim 1 further comprising a suction vacuum operably linked to the instrument.

7. The system of claim 1 , wherein the interrogation power level is less than 10% of the maximum power level of the ablation laser.

8. The system of claim 1 , wherein the ablation power level is greater than 50% of the maximum power level of the ablation laser.

9. The system of claim 1 , wherein the processor determines whether the acquired signal is indicative of the presence of the Raman reporter in and/or upon the scanning point by:
determining a comparison index between the acquired signal and a referenced signal of the administered Raman particle; and
evaluating the determined comparison index to determine if the index exceeds a pre-defined threshold.

10. The system of claim 1 , comprising:
a raster scanning device for positioning the instrument over the target tissue.

11. The system of claim 1 , wherein, upon the determination of the presence of the Raman particle in and/or upon the scanning point, the ablation power level of the ablation laser is at a power level that does not cause damage to tissue exposed to electromagnetic radiation at the ablation power level unless the Raman particle is present therein or thereupon.

12. The system of claim 1 , wherein the Raman particle can be detected at a sensitivity of 10 −12 M or better.

13. The system of claim 1 , wherein the capping agent comprises a citrate.

14. The system of claim 1 , wherein the excitation light is in the visible to near infrared range.

15. The system of claim 1 , wherein the excitation light is near infrared.

16. The system of claim 1 , wherein the nanoscale substrate comprises a member selected from the group consisting of gold, silver, copper, sodium, potassium, chromium, aluminum, and lithium.

17. The system of claim 1 , wherein the nanoscale substrate has a spherical shape.

18. The system of claim 1 , wherein the nanoscale substrate has a non-spherical shape.

19. The system of claim 18 , wherein the non-spherical shape of the nanoscale substrate or a cross-section thereof is a member selected from the group consisting of a rod, a star, a shell, an ellipse, a triangle, a pyramid, a cube, and a cage.

20. The system of claim 1 , wherein the excitation light source produces near infrared excitation light having a frequency that is in resonance with a major absorption band of the SERRS nanoparticle.

21. The system of claim 20 , wherein the excitation light source is a laser that produces near infrared light.

22. The system of claim 1 , wherein the excitation light source produces visible excitation light having a frequency that is in resonance with a major absorption band of the SERRS nanoparticle.

23. The system of claim 22 , wherein the excitation light source is a laser that produces visible light.

24. The system of claim 1 , wherein the Raman active agent is in direct contact with the nanoscale substrate and positioned a distance between 1 nm and 3 nm from the nanoscale substrate.

25. The system of claim 1 , wherein the Raman particle comprises a layer that encapsulate the nanoscale substrate, wherein the layer comprises silica.

26. The system of claim 25 , wherein the layer has an average thickness between greater than or equal to 10 nm and less than or equal to 30 nm.

27. The system of claim 26 , wherein the layer has an average thickness between greater than or equal to 20 nm and less than or equal to 30 nm.

28. The system of claim 1 , wherein the Raman active agent comprises a phthalocyanine, a naphthalocyanine, a chalcogen-based dye, an azomethine, a squaraine, and/or a xanthine.

Assignees

• Memorial Sloan Kettering Cancer Center

Inventors

• Kircher Moritz
• Toledo-Crow Ricardo

Classifications

• A61B2090/3937

  Visible markers · CPC title

• A61B2018/00577

  Ablation · CPC title

• G01N21/65

  Raman scattering · CPC title

• A61B5/0075 Primary

  by spectroscopy, i.e. measuring spectra, e.g. Raman spectroscopy, infrared absorption spectroscopy (A61B5/0071 takes precedence) · CPC title

• A61B18/02

  by cooling, e.g. cryogenic techniques · CPC title